GENE ONLINE|News &
Opinion
Blog

2021-10-21| ChinaIPO

Shanghai Startup Poised for $325M IPO on Nasdaq

by Tyler Chen
Share To
With just 2 years into operation, Shanghai startup LianBio is set to go public on the Nasdaq. The firm release the term for the initial public offering (IPO) on Oct. 20, and it plans to raise $325 million to complete Phase 3 clinical trials of its lead drug candidates.

LianBio said it will launch 20 million shares with $15 to $17 per share and a 30-day option to purchase up to an additional 3 million shares.

GO Prime with only $1.49 now

LATEST
Novel RAGE Antagonist Stirs Hopes for Countering Diabetic Complications
2021-12-07
AstraZeneca Blocks Private Equity Buyout of Swedish Pharma Sobi
2021-12-06
Coherent Biopharma, WuXi STA Collab Takes a Crack at Peptide-Drug Conjugates
2021-12-06
How CDMOs are Restructuring the Biopharma Landscape – An Interview with Bobby Sheng
2021-12-06
BeiGene launches IPO on Shanghai’s STAR market to raise $3B
2021-12-03
Novartis, UCB Take Aim at Parkinson’s Disease Under $1.65 Billion Collab
2021-12-03
Atara Biotherapeutics’ First-In-Class Allogeneic T-Cell Therapy Accepted for EMA Review
2021-12-02
EVENT
2021-12-13
63rd ASH ANNUAL MEETING AND EXPOSITION
Georgia, USA
2021-12-28
BIOHK2021
Hong Kong, China
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!